| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 7.47% | -5.53% | 8.54% | 28.03% | 24.94% | 19.06% | 13.35% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% |
| EBITDA Margin | 18.14% | 5.45% | 19.20% | 34.39% | 30.68% | 26.45% | 21.07% | 21.53% | 17.36% | 20.38% | 21.98% | 23.15% |
| Net Margin | 6.62% | -4.02% | 6.51% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% |
| Current Ratio | 8.37 | 8.41 | 7.02 | 2.47 | 2.48 | 2.83 | 13.28 | 2.12 | 9.63 | 8.74 | 5.50 | 7.58 |
| Quick Ratio | 7.12 | 7.28 | 5.75 | 1.88 | 1.99 | 2.53 | 12.15 | 1.80 | 8.08 | 7.57 | 4.54 | 6.42 |
| Debt / Equity | 0.26 | 0.27 | — | — | — | — | — | — | — | — | — | — |
| ROE | 2.32% | -1.29% | 2.11% | 9.73% | 7.33% | 3.92% | 2.02% | 2.70% | 4.79% | 6.92% | 7.61% | 7.31% |
| ROA | 1.66% | -0.90% | 1.47% | 7.37% | 5.44% | 3.15% | 1.53% | 2.15% | 3.81% | 4.04% | 6.39% | 6.37% |
| Asset Turnover | 0.25 | 0.22 | 0.23 | 0.32 | 0.28 | 0.19 | 0.19 | 0.25 | 0.19 | 0.36 | 0.57 | 0.50 |
| Book Value / Share | 37236.42 | 35266.78 | 34964.67 | 33255.59 | 30.56 | 28.37 | 21.54 | 13537.60 | 15.11 | 4.95 | 3.66 | 3.36 |
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves biopharmaceutical drug developers, contract development and manufacturing organizations (CDMOs), and other life science companies across North America, Europe, and Asia Pacific. The company offers products in four main categories: filtration and fluid management, its largest segment; chromatography, including OPUS pre-packed columns and high-performance resins like AVIPure HiPer for viral vectors; proteins, such as Protein A ligands and affinity chromatography components; and process analytics, featuring slope spectroscopy systems like SoloVPE and FlowVPE. Repligen's technologies enable purification, cell culture growth, and process monitoring, addressing key needs in biologics production for next-generation modalities like gene therapy.